| |
Newsroom /
Medical
/
Medical
/
Pfizer Doing its Every Bit to Save its Blockbuster From an Expected Free Fall
Pfizer Doing its Every Bit to Save its Blockbuster From an Expected Free Fall
With billions of dollars at stake, Pfizer is doing its every bit to save Lipitor from a complete free-fall resulting from its patent expiry later this month.
Noida,
Uttar pardesh,
India
(prbd.net)
11/11/2011
A new study from IMARC Group entitled “US Cholesterol Lowering Agents Market Report & Forecast: On the Edge of a Patent Cliff” finds that upon its patent expiry in November 2011, Lipitor - the world’s largest selling drug is expected to experience a complete freefall with its sales in the next few years declining to levels that are only a fraction of its 2010 value. The study has conducted individual long range forecasts for Atorvastatin (Lipitor) and all other major in-market and pipeline dyslipidemia drugs. Findings from the study suggest that brands indicated for dyslipidemia are expected to witness a more rapid and aggressive generic erosion than most other therapeutic classes. According to Ganeshwar Ramamurthy, an analyst at IMARC group, “Historical erosion curves of Zocor (Simivastatin) and other patent expired dyslipidemia drugs suggest that brands belonging to this class are significantly more vulnerable towards generic cannibalization compared to other classes.
Pfizer, the manufacturer of Lipitor, however, is not expected to give up so easily. The company is currently making deals with drug-benefit plans and providing rebates to patients in order to promote the continued use of branded Lipitor. In the long term, Pfizer plans to sell an over-the-counter version of Lipitor, which if successful, might be able to partially counter generic competition and potentially mitigate some of its losses. The nonprescription version of Lipitor, however, will not be available immediately after its patent expiry as a significant amount of time will be needed to convince the US FDA that consumers could take the drug without a physicians prescription.
The study finds that apart from Atorvastatin (Lipitor), nine other dyslipidemia drugs are expected to lose their patents during 2011-2016 creating a total opportunity of US$ 15.9 billion during the period. Projections from the report suggest that by 2016 around 92% of the entire US dyslipidemia market will be accounted by generics.
IMARC’s new report entitled “US Cholesterol Lowering Agents Market Report & Forecast: On the Edge of a Patent Cliff” provides an analytical and statistical insight into the US Cholesterol Lowering agents Market. The study that has been undertaken using both desk-based as well as qualitative primary research has analyzed the following aspects of this market:
Key Aspects Analyzed:
Understanding the Epidiomology of Dyslipidemia in the US:
Focus of the Analysis:
• Current and future size of the dyslipidemia patient pool
• Current and future prevalence of dyslipidemia
• Current and future diagnosis rates for dyslipidemia
• Current and future drug treatment rates for dyslipidemia
Comprehensive Evaluation of the US Cholesterol Lowering Agents Market:
Classes Covered: Statins, Fixed Dose Combinations, Ion Exchange Resins, Fibrates, Other Cholesterol Triglyceride Regulators, Omega-3 Acid Ethyl Esters and CETP Inhibitors
Molecules Covered: Atorvastatin, Rosuvastatin, Simvastatin, Pravastatin, Fluvastatin, Lovastatin, Pitavastatin, Ezetimibe/Simvastatin, ER Niacin/Simvastatin, Atorvastatin/Amlodipine, ER Naicin/Laropiprant, Ezetimibe/Atorvastatin, ER Niacin/Laropiprant/Simvastatin, Colesevelam, Cholestyramine, Colestipol, Fenofibrate, Fenofibric Acid, Gemfibrozil, Dalcetrapib, Anacetrapib
Focus of the Analysis for Each Class & Molecule:
• Drug Overview
• Historical Sales
• Key Players and Brands in the Market
• Patent Expiries and Generic Launch
• Sales Forecast
Comprehensive Evaluation of Generic Opportunities in the US Cholesterol Lowering Agents Market:
• Historical Patent Expiries and the Evolution of Generic Drugs
• Historical Value and Volume share of Brands and Generics
• Future Patent Expiries and Generic Launches
• Value and Volume Forecasts for Brands and Generics
Information Sources:
Information has been sourced from both primary and secondary sources:
• Primary sources include industry surveys and face to face/telephone interviews with industry experts.
• Secondary sources include proprietary databases and search engines. These sources include company websites and reports, books, trade journals, magazines, white papers, industry portals, government sources and access to more than 4000 paid databases.
To buy the complete report or to get a free sample:
Call: +91-120-425-6531 (Asia), +1-631-791-1145 (America)
email: sales@imarcgroup.com
To know more please visit: http://www.imarcgroup.com/
About
For more than 5 years, the International Market Analysis Research and Consulting Group has been a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
|